Takara BioFRA:TF2 71 Gross Margin % is 51.32% as of Mar. 2026, which is 11% below its 10-year median of 57.81. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 736 Biotechnology companies, Takara Bio ranks worse than 60.05% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Takara Bio's Gross Profit for the
three
months ended in Mar. 2026 was €33.4 Mil. Takara Bio's Revenue for the
three
months ended in Mar. 2026 was €65.0 Mil. Therefore, Takara Bio's Gross Margin % for the quarter that ended in Mar. 2026 was 51.32%.
Warning Sign:
Takara Bio Inc gross margin has been in long-term decline. The average rate of decline per year is -6.1%.
The historical rank and industry rank for Takara Bio's Gross Margin % or its related term are showing as below:
FRA:TF2'
s Gross Margin % Range Over the Past 10 Years
Min: 50.25 Med: 57.81 Max: 72.69
Current: 50.25
During the past 13 years, the highestGross Margin % of Takara Bio was 72.69%. The lowest was 50.25%. And the median was 57.81%.
FRA:TF2's Gross Margin % is ranked worse than 60.05% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs FRA:TF2: 50.25
Takara Bio had a gross margin of 51.32% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Takara Bio was -6.10% per year.
Takara Bio (FRA:TF2) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Takara Bio had a gross margin of 51.32% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Takara Bio Gross Margin % Related Terms
Takara Bio Gross Margin % Historical Data
* Premium members only.
The historical data trend for Takara Bio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Takara Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Takara Bio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Takara Bio (FRA:TF2) has a Gross Margin % of 51.32% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Takara Bio and its competitors. This is 11% below median its historical median of 57.81. Over the past decade, Takara Bio's Gross Margin % has ranged from 50.25 to 72.69. According to the industry distribution chart, Takara Bio ranks #442 out of 736 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Takara Bio's Gross Margin % too high?
Takara Bio's current Gross Margin % of 51.32% is 11% below median its 10-year median of 57.81. Over the past 10 years, this metric has ranged from a low of 50.25 to a high of 72.69. The Biotechnology industry median Gross Margin % is 60.91. Takara Bio's value of 51.32% is 15.7% below this industry median. Based on the distribution chart, Takara Bio ranks #442 out of 736 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #442 out of 736 companies for Gross Margin %. This places Takara Bio in the lower half of its industry. The industry median Gross Margin % is 60.91. Takara Bio's value of 51.32% is 15.7% below this benchmark. Historically, Takara Bio's own Gross Margin % has ranged from 50.25 to 72.69 over the past decade. While the company's 10-year median is 57.81 vs. the industry median of 60.91, Takara Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current Gross Margin % of 51.32% is 15.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Gross Margin % is 51.32%, which is 11% below median its own 10-year median of 57.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current Gross Margin % is 51.32%, which is 11% below median its 10-year median of 57.81 and 15.7% below the Biotechnology industry median of 60.91. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Gross Margin % is 51.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
Gross Margin %: 51.32% (11% below median its 10-year median of 57.81)
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
Industry Position: 15.7% below the Biotechnology median (#442 of 736)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
